The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (272 million pounds) spanning five years over Washington's request for confidential data.
This rejection became public following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesman has since clarified that the US was seeking genetic material for scientific study and commercial purposes but was unwilling to guarantee the benefits from future treatments.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for further dialogue to find a deal agreeable to both sides so the country's critical HIV programme can proceed.
Wider Context
This development comes after a similar situation in Kenya, where a court halted a similar health funding agreement following legal challenges were raised about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking direct bilateral deals to boost transparency and accountability.
Based on reports, Sixteen nations in Africa have to date signed these new agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery without any certainty that the resulting innovations would be available to our citizens should a future pandemic arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one health agreements were undermining systems previously established via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This mechanism is intended to ensure that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to ongoing dialogue with our US partners on how future collaboration could be designed in a manner that honours the independence and interests of both nations."
Health Experts Response
Medical experts stated it recognised the official position, but recommended that negotiations must proceed since much of the country's Aids initiatives relied on external financing.
"If specific concerns arise, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it said.
The halted deal emphasises the complex tensions between receiving crucial foreign assistance and safeguarding local interests in an increasingly interconnected world.